FDA Adds Eye Warning to Ozempic, Wegovy, Mounjaro and Zepbound: What to Watch For
Direct answer: On November 9, 2026, the U.S. Food and Drug Administration (FDA) required all GLP-1 medicines — including Ozempic, Wegovy, Mounjaro, and Zepbound — to add a warning about a potential increased risk of NAION, a rare eye condition that can cause sudden, painless vision loss in one eye, including permanent vision loss. In the FDA's review of 126 clinical trials covering 134,253 patients, 15 probable NAION cases appeared: 10 in people taking a GLP-1 drug and 5 in people taking a placebo. The rate was 6.4 cases per 100,000 person-years with a GLP-1 drug, compared with 3.8 per 100,000 person-years in comparison groups, according to the FDA, November 9, 2026.
What is NAION?
NAION stands for non-arteritic anterior ischemic optic neuropathy. It happens when blood flow to the front part of the optic nerve drops. The result is sudden, painless vision loss in one eye, sometimes in both eyes.
Vision loss from NAION is often noticed on waking. Other signs include blurred or missing areas of vision, color distortion, and reduced central sharpness, according to the FDA communication. The condition can lead to permanent vision loss. Its underlying cause is not completely understood, according to the FDA.
Risk factors the FDA lists for NAION include smoking, diabetes, high blood pressure, sleep apnea, anemia, and kidney disease. These conditions often overlap with the reasons people take GLP-1 medicines in the first place.
Which medicines are affected?
The warning applies to the whole GLP-1 receptor agonist class, not to one brand. NAION cases have been reported for all currently marketed GLP-1 RA products, according to the FDA, November 9, 2026.
The medicines include semaglutide (Ozempic, Rybelsus, Wegovy), tirzepatide (Mounjaro, Zepbound), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), exenatide, lixisenatide combinations (Soliqua), liraglutide plus insulin degludec (Xultophy), and orforglipron (Foundayo), approved in 2026. These medicines are prescribed for type 2 diabetes, for weight management, or for both.
What did the FDA find?
The FDA began its review after a July 2024 study in JAMA Ophthalmology reported a link between semaglutide and NAION. The agency then reviewed clinical trial data, animal data, and postmarketing data, including observational studies and case reports.
The animal data did not identify a mechanism for how GLP-1 use could raise NAION risk, according to the FDA. The agency still concluded that the combined evidence supports a potential increased risk of rare NAION events in people taking GLP-1 medicines.
| Group | Patients | Person-years | Probable NAION cases | Rate per 100,000 person-years |
|---|---|---|---|---|
| GLP-1 drug | 78,217 | 156,947 | 10 | 6.4 |
| Comparator (placebo or other diabetes drug) | 56,036 | 131,932 | 5 | 3.8 |
The table above comes from the FDA meta-analysis of 126 randomized trials, published November 9, 2026. All 5 comparator cases were in people who received a placebo. No cases appeared in people who received another non-GLP-1 glucose-lowering medicine.
What did the FDA's real-world study show?
The FDA also ran a retrospective study using its Sentinel real-world data system. It covered adults with type 2 diabetes who started a GLP-1 drug, an SGLT-2 inhibitor, or a DPP-4 inhibitor between 2019 and 2024.
NAION rates in that study ranged from 26 to 32 events per 100,000 person-years: 30 to 32 for GLP-1 drugs, 31 for SGLT-2 inhibitors, and 26 for DPP-4 inhibitors. The risk increase was not statistically significant compared with SGLT-2 inhibitors (hazard ratio 1.19, 95% CI 0.91 to 1.54). Compared with DPP-4 inhibitors, the hazard ratio was 1.43 (95% CI 1.02 to 2.01), according to the FDA, November 9, 2026.
Published observational studies that the FDA reviewed also reported an increased NAION risk in people with type 2 diabetes who started a GLP-1 drug, compared with those who started a DPP-4 inhibitor or an SGLT-2 inhibitor. The FDA noted that no single data source settled the question on its own.
Is this a recall?
No. No GLP-1 product is being withdrawn, recalled, or restricted. The FDA is requiring only a labeling change: application holders must add NAION risk information to the Warnings and Precautions section of each product's labeling.
Europe moved earlier on the same concern. In 2025, the European Medicines Agency's safety committee said NAION may affect up to 1 in 10,000 people taking semaglutide, according to Reuters, November 9, 2026. Warnings about semaglutide and NAION were added to European labels for Wegovy and Ozempic in June 2025.
What should you do if you notice vision changes?
- Report sudden, painless vision loss, a visual field deficit, or any other visual change in one eye to your clinician right away.
- Ask for a prompt referral to an ophthalmologist if NAION is suspected. The FDA advises clinicians to refer patients with suspected NAION promptly to an eye specialist.
- Do not stop a prescribed GLP-1 medicine on your own. The FDA did not tell patients to stop these medicines.
- Bring a list of your medicines, including the brand name and dose, to the eye appointment.
Frequently asked questions
Does this warning mean GLP-1 drugs cause blindness?
No. The FDA concluded there is a potential increased risk of a rare condition, not proof that the drugs cause it. The agency found signals pointing to a possible association, but it did not determine whether GLP-1 drugs can cause NAION.
How rare is NAION with these medicines?
In the FDA's trial analysis, 15 probable cases appeared among 134,253 patients across 126 trials. The rate was 6.4 cases per 100,000 person-years with a GLP-1 drug, versus 3.8 per 100,000 person-years in comparison groups, according to the FDA, November 9, 2026.
Should I stop taking my GLP-1 medicine?
Do not stop a prescribed medicine without talking to your clinician. The FDA's action is a labeling change, not a stop-use order. Your clinician can weigh the vision warning against the medicine's benefits for your diabetes or weight.
What symptoms should I watch for?
Sudden, painless loss of vision in one eye, a missing area in your field of vision, blurred vision, color distortion, or reduced central sharpness. These changes are often noticed on waking. Report them immediately and ask for an ophthalmology referral.
Does the warning cover compounded GLP-1 products?
The FDA requirement applies to approved GLP-1 medicines and their labeling. Compounded products are not FDA-approved medicines, and they do not carry FDA-approved labeling. If you use a compounded product, ask your prescriber or pharmacist what applies to you.
Key Takeaway
The FDA's new warning covers every GLP-1 medicine, but NAION remains rare — 10 cases versus 5 in 126 trials. The one action that matters is speed: sudden, painless vision loss in one eye should be reported right away and checked by an eye specialist.
Sources: U.S. Food and Drug Administration, Drug Safety Communication, “FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Due to Potential Increased Risk of Rare But Serious Eye Condition,” published November 9, 2026; Reuters, “US FDA orders new eye risk warnings for Ozempic, Zepbound,” November 9, 2026; USA Today, “FDA says popular GLP-1 drugs linked to rare risk of vision loss, blindness,” November 9, 2026.
This post was created with the help of AI tools and reviewed for accuracy against the sources cited above. It is general information only, not medical advice. For decisions about your own medicine, please talk to your doctor or pharmacist.
